目的 探讨心可舒丸联合曲美他嗪治疗冠心病心绞痛的临床疗效。方法 选取2017年6月-2019年6月南阳医学高等专科学校第一附属医院收治的冠心病心绞痛患者128例，随机分为对照组（64例）和治疗组（64例）。对照组口服盐酸曲美他嗪片，20 mg/次，3次/d。治疗组在对照组基础上口服心可舒丸，4粒/次，3次/d。两组患者均治疗1个月。观察两组患者临床疗效，同时比较治疗前后两组患者内皮素-1（ET-1）和一氧化氮（NO）水平，及心绞痛发作持续时间和次数。结果 治疗后，对照组临床有效率和心电图有效率分别为81.25%和75.00%，分别显著低于治疗组的93.75%和92.19%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组ET-1明显下降（P<0.05），而NO明显升高（P<0.05），且治疗组ET-1和NO水平明显好于对照组（P<0.05）。治疗后，两组心绞痛发作次数明显减少（P<0.05），发作持续时间明显缩短（P<0.05），且治疗组心绞痛发作持续时间和次数小于对照组（P<0.05）。结论 心可舒丸联合曲美他嗪治疗冠心病心绞痛，可有效改善患者心绞痛症状，疗效确切，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Xinkeshu Pills combined with trimetazidine in treatment of angina pectoris of coronary heart disease. Methods Patients (128 cases) with angina pectoris of coronary heart disease in the First Affiliated Hospital of Nanyang Medical College from June 2017 to June 2019 were randomly divided into control (64 cases) and treatment (64 cases) groups. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were po administered with Xinkeshu Pills on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the level of ET-1 and NO, and duration and frequency of angina attack in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and electrocardiographic effect in the control group were 81.25% and 75.00%, which were significantly lower than 93.75% and 92.19% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the ET-1 levels in two groups were significantly decreased (P < 0.05), but NO levels were significantly increased (P < 0.05), and the ET-1 and NO in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the frequency of angina attack in two groups was significantly decreased (P < 0.05), duration of angina attack in two groups was significantly shortened (P < 0.05), and the duration and frequency of angina attack in the treatment group were significantly less than that in the control group (P < 0.05). Conclusion Xinkeshu Pills combined with trimetazidine in treatment of angina pectoris of coronary heart disease can effectively improve the symptoms of angina pectoris, which has a certain clinical application value.

R972

河南省科技发展计划项目（182102510123）